Recent Acquisitions Roivant Sciences has been actively acquiring companies like Dermavant Sciences and Immunovant, expanding its portfolio. Leveraging these acquisitions, there are potential cross-selling opportunities to introduce complementary products and services to existing and new clients.

Collaboration with Bayer The partnership with Bayer to create Pulmovant presents a strategic collaboration opportunity to combine expertise and resources. This collaboration opens doors for joint sales efforts, leveraging the reputation and networks of both companies to tap into new markets and increase revenue streams.

Investments from Exchange Traded Concepts With a significant investment from Exchange Traded Concepts, Roivant Sciences demonstrates financial stability and attractiveness to potential investors. This financial backing can enhance credibility in the market and attract collaborations or partnerships with other investment firms, leading to potential sales opportunities.

Tech-Focused Vants Through its technology-focused Vants, Roivant Sciences showcases innovation and a cutting-edge approach to healthcare technology. Leveraging these advanced technologies can be a compelling sales proposition to tech-savvy clients looking for modern solutions, creating opportunities for technology-driven product sales and partnerships.

Strategic Partnerships with Pharma Giants Strategic partnerships with pharmaceutical giants like Roche and Sanofi highlight Roivant Sciences' industry reputation and collaboration capabilities. These partnerships can be leveraged to explore joint sales and distribution channels, tapping into the extensive networks and resources of these partners to drive sales growth.